SE1-1Capsule Expression among Oral Streptococci

Moon H. Nahm

University of Alabama at Birmingham, USA

SE1-2Two cases of bacteremia due to S. oralis expressing serotype 3 pneumococcal capsule

Kei Kasahara

Nara Medical University, Japan

SE2-1Predication of β-lactam resistance phenotype

Jie Feng

Institute of Microbiology, Chinese Academy of Sciences, China

SE2-2 Exploring pneumococcal virulence factors via molecular evolutionary analysis

Masaya Yamaguchi

Osaka University Graduate School of Dentistry, Japan

SE3-1Survival strategy of S. pneumoniae by hijacking host autophagy

Michinaga Ogawa

National Institute of Infectious Diseases, Japan

SE3-2Capsule serotype-dependent evasion of resident macrophage capture

Jing-Ren Zhang

Tsinghua University, China

LS1-1Epidemiology of adult pneumococcal infections in Japan

Koji Kuronuma

Sapporo Medical University School of Medicine, Japan

LS1-2Current situation of pneumococcal disease in children in Japan

Naruhiko Ishiwada

Chiba University, Japan

SE4-1Economic evaluation of vaccines and vaccination programs:
Guides from global and Japanese experiences

Manabu Akazawa

Meiji Pharmaceutical University, Japan

SE4-2he Health Technology Assessment of pneumococcal vaccination in Japan:
Costeffectiveness and value assessment

Ataru Igarashi

Yokohama City University School of Medicine, Japan

P-1 Current situation of pneumococcal disease in children in Japan Epidemiological change of invasive pneumococcal disease in children after the introduction of 13-valent pneumococcal conjugate vaccine in Japan

Noriko Takeuchi

Department of Infectious Diseases, Medical Mycology Research Center, Chiba, Japan

P-2 Pneumococcal Meningitis in Adults in 2014-2018 after Introduction of Pediatric 13-valent Pneumococcal Conjugate Vaccine in Japan

Hiroyuki Fujikura

National Institute of Infectious Diseases, Tokyo, Japan

P-3 Association of Serotype with Clinical Presentation of Invasive Pneumococcal Disease in Adults, Japan

Kosuke Tamura

Department of Research Planning, Toyama Institute of Health, Toyama, Japan

P-4 Changes in the notification rate of Invasive Pneumococcal Disease in Japan during the COVID-19 pandemic: Descriptive assessment of national surveillance data

Reiko Shimbashi

Surveillance Analysis Unit, Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo, Japan

P-5 Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in patients with hematological malignancies who were outside recommended ages for routine vaccination

Kenichi Takeshita

Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan

P-6 A Novel Real-time PCR Assay Targeting lytA, piaB, and SP2020 for Identification of Streptococcus pneumoniae

Bhim Gopal Dhoubhadel

Department of Respiratory Infections, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan

P-7 Multiple Serotypes of Pneumococci in Patients With Pneumonia and Their Associated Risk Factors in Japan

Bhim Gopal Dhoubhadel

Department of Respiratory Infections, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan

P-8 Relationship between the Opacity Variance of Streptococcus pneumoniae Colonies and the Clinical Features of Adult Pneumococcal Pneumonia

Kazuko Yamamoto

Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan

P-9 Long-term impact of introduction of pneumococcal conjugate vaccines for children on adult pneumococcal pneumonia in Japan: Two multicenter observational studies from 2011 to 2020

Haruka Maeda

Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan

P-10 Distribution and variation of serotypes and pneumococcal surface protein A clades of Streptococcus pneumoniae strains isolated from adult patients with invasive pneumococcal disease in Japan

Bin Chang

Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan

P-11 Seroepidemiological Analysis of Anti-Pneumococcal Surface Protein A (PspA) Immunoglobulin G by Clades in Japanese Population

Saeko Morino

Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan

P-12 Establishment of PspA-optimized OPA for human sera

Yuka Koizumi

The Research Foundation for Microbial Diseases of Osaka University, Osaka, Japan

P-13 Exposure to Cigarette Smoke Enhances Pneumococcal Transmission Among Littermates in an Infant Mouse Model

Daichi Murakami

Department of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan

P-14 Involvement of C-type Lectin Receptors in Neutrophil-Mediated Host Defense against Pulmonary Streptococcus pneumoniae Infection

Keiko Ishii

Department of Medical Microbiology, Mycology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan

P-15 Pneumococcal surface protein A and glycolipid vaccine augments generation of long-lived plasma cells that produce antigen-specific IgG

Koji Hayashizaki

Department of Bacteriology, The Jikei University School of Medicine, Tokyo, Japan

P-16 The Roles of Transient Receptor Potential Vanilloid 1 and 4 in Pneumococcal Nasal Colonization and Invasive Disease

Masamitsu Kono

Department of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan

P-17 Effects of specific surface protein antigen, PspK, of non-encapsulated streptococcus pneumoniae on nasal carriage, shedding, and transmission among littermates of infant mice

Muneki Hotomi

Department of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan

P-18 Investigation on the virulence of non-encapsulated Streptococcus pneumoniae using liquid agar pneumonia model

Muneki Hotomi

Department of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan

P-19 Genetic linkage analysis identifies pneumococcal susceptibility locus in mice

Ryodai Shindo

Department of Microbiology and Infectious Disease, Toho University School of Medicine, Tokyo, Japan

P-20 Bacteriological and molecular biological characterization of serotype 24F ST162 Streptococcus pneumoniae dependent on CO2 and temperature in Japanese children

Jun Kobayashi

Department of Laboratory Medicine, Nagano Children's Hospital, Nagano, Japan

P-21 Unbiased homeologous recombination during pneumococcal transformation allows for multiple chromosomal integration events

Jun Kurushima

Department of Bacteriology, School of Medicine, Gunma University, Gunma, Japan

P-22 Whole genome analysis of a multidrug-resistant Streptococcus pneumoniae isolate from a patient with invasive pneumococcal infection

Hiroyuki Honda

Department of Microbiology, Sapporo Medical University School of Medicine, Sapporo, Japan

P-23 Clonality Analysis of Streptococcus pneumoniae in Clinical Specimens

Delly C. Lestari

Department of Bacterial Infections, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan

P-24 Bacterial transcytosis of Streptococcus pneumoniae across the host cells: An in vitro model for analysis of invasive potential

Jun-ichi Kanatani

Department of Bacteriology, Toyama Institute of Health, Toyama, Japan

P-25 Nasal epithelial barrier dysfunction involved in non-hematogenous pneumococcal dissemination to brain tissue

Yuki Takahara

Department of Oral Molecular Microbiology, Osaka University Graduate School of Dentistry, Osaka, Japan

PL1-1Nasal delivery of a universal protein antigen identified by CRISPRi-seq induces broad protection from pneumococcal superinfection

Jan-Willem Veening

University of Lausanne, Switzerland

ESY1-1Pneumococcal polysaccharide vaccine (PPSV23) for older adults in Japan

Hideaki Nagai

National Hospital Organization Tokyo Hospital, Japan

ESY1-2Current status and needs for pneumococcal polysaccharide vaccine (PPSV23) in older adults of South Korea

Joon Young Song

Korea University College of Medicine, South Korea

ESY1-3Surveillance of Invasive Pneumococcal Disease in Taiwan

Cheng-Hsun Chiu

Chang Gung Memorial Hospital, Taiwan

PL2-1Pneumococcal-Host Interactions Affecting Carriage and Transmission

Jeffrey N. Weiser

New York University, USA

SE5-1Global impact of PCV10/13 on invasive pneumococcal disease serotype distribution and incidence rates among children and adults: results from the PSERENADE project

Julia C. Bennet and Maria Garcia Quesada

Johns Hopkins Bloomberg School of Public Health, USA

SE5-2Dynamic changes in serotype distribution of invasive pneumococcal disease among adults after introduction of pediatric pneumococcal conjugate vaccine (PCV) in 2013–2019 in Japan

Kazunori Oishi

Toyama Institute of Health, Japan

SE6-1Molecular epidemiology of pneumococcal isolates in Japan

Satoshi Nakano

National Institute of Infectious Diseases, Japan

SE6-2Changes in molecular epidemiology in Korea after the introduction of Extended valency PCVs in Korean children

Hyunju Lee

Seoul National University Bundang Hospital, South Korea

LS2-1Lessons learned from Pandemic: Similarity and difference in COVID-19 and Influenza

Kazuhiro Tateda

Toho University of Medicine, Japan

SE7-1The low carriage prevalence of pneumococcus among community-dwelling older people

Konosuke Morimoto

Nagasaki University, Japan

SE7-2Using community vaccine type pneumococcal carriage to evaluate of reduced dosing PCV schedules in Vietnam

Lay-Myint Yoshida

Nagasaki University, Japan

SE8-1The immunogenicity of sequential administration of PCV13/ PPSV23 in pneumococcal vaccine-naïve adults ≥ 65 years of age

Momoyo Azuma

Tokushima University Hospital, Japan

SE8-2Pneumococcal vaccination in adult allogeneic hematopoietic stem cell transplant recipients

Keiji Okinaka

National Cancer Center Hospital, Japan

SE9-1Delivery of Streptococcus pneumoniae capsular polysaccharides by recombinant attenuated Salmonella vaccines

Qingke Kong

South Western University, China

SE9-2Broad-spectrum vaccine candidate using bivalent recombinant fusion proteins of Pneumococcal Surface Protein A (PspA) against Streptococcus pneumoniae

Hiroki Nakayama

The Research Foundation for Microbial Diseases of Osaka University, Japan

SE9-3Phase 3 trial to evaluate safety, tolerability and immunogenicity of V114 followed by 23-valent pneumococcal polysaccharide vaccine 6 months later in at-risk adults aged 18–49 years (PNEU-DAY)

Luwy Musey

Merck & Co., Inc., USA

SE9-4 Pivotal Study of the Safety, Tolerability and Immunogenicity of PCV20 in Adults

Wendy Watson

Pfizer, Inc,, USA

JSE-1Future Perspectives of Research and Development in Infectious Disease Prevention and Future Expectations of Clinical Applications

Norio Ohmagari

National Center for Global Health and Medicine, Japan

JSE-2Past, now and future of monoclonal antibodies: From treatment to prevention in infectious disease

Susanna Esposito

Pediatrics at the Faculty of Medicine and Surgery of the University of Parma, Italy